Subscribe to “CTRI Bulletin”
Submit a paper

"CTRI Bulletin"
#3,(12),2020.

CTRI BULLETIN №3 (12) 2020

Journal Information: Read
Chief Editor: Ergeshov A.E.
Year of foundation: 2017
ISSN (Print): Browse
Publisher site: http://critub.ru
http://tb-bulletin.ru

Return to archive

CONTENT

1)

WHO: TB control in the European Region. Operational TB research

Based on the World Health Organization publications

5 READ MORE
2)

Non-virological laboratory markers of COVID-19

Abdullaev R.Yu., Komissarova O.G.

12 READ MORE
3)

Pulmonary tuberculosis and the thyroid gland

Polyakova A.S., Bagdasaryan T.R., Romanov V.V., Ergeshov A.E.

17 READ MORE
4)

Predictors of unfavourable treatment outcome in TB patients receiving treatment regimens for susceptible tuberculosis

Saenko S.S., Sterlikov S.A., Rusakova L.I., Lekhleider M.V., Pirogova N.D., Surnacheva I.F., Gudenkov M.A., Svicharskaya A.K., Podgainaya O.A., Kononenko Yu.S., Novikova T.V., Yukhnova E.A., Frolov E.G., Gromov A.V., Gaevaya I.S.

24 READ MORE
5)

The morphology of healing processes in the lung tissue of patients with drug resistant pulmonary TB after preoperative intravenous laser blood irradiation

Lepekha L.N., Aliev V.K., Krasnikova E.V., Bagirov M.A.

35 READ MORE
6)

On the question of effectiveness and safety of bedaquiline-containing regimens in the treatment of pulmonary TB with multiple or extensive drug resistance in senior children and adolescents

Krushinskaya E.A., Panova L.V., Ovsyankina E.S.

43 READ MORE
7)

Chronic obstructive pulmonary disease: from recommendations to practice in the Republic of Tatarstan

Vizel I.Yu., Salakhova I.N., Shmelev E.I., Vizel А.А., Vafina A.R., Shakirova G.R., Dyakova E.V.

49 READ MORE
8)

The standards of knowledge of the international conception of chronic obstructive pulmonary disease

Liverko I.V., Tashmetova G.T.

58 READ MORE
9)

Vascular stiffness and pulmonary fibrosis as predictors of right ventricular systolic dysfunction in patients with chronic hypersensitivity pneumonitis

Leonova E.I., Shmelev E.I., Shergina E.A.

65 READ MORE
10)

The culture method for mycobacteria studies. Solid growth media  

Larionova E.E., Andrievskaya I.Yu., Andreevskaya S.N., Smirnova T.G., Sevastyanova E.V.

75 READ MORE

WHO: TB CONTROL IN THE EUROPEAN REGION.

OPERATIONAL TB RESEARCH

Article 1.Page 5.
ARTICLE TITLE:

WHO: TB CONTROL IN THE EUROPEAN REGION. OPERATIONAL TB RESEARCH

DOI: 10.7868/S2587667820030012

AUTORS:

 

DESCRIPTION OF ARTICLE:

Submitted as of 21.05.2020

Worldwide, TB remains a top infectious killer, given 1.5 million people die annually from the disease. Every day about 30.000 people fall ill with the disease, which is preventable. Effective management and cure of drug resistant TB remains a priority measure of TB control. Therefore, the WHO Regional Office for Europe in association with the WHO Representative Office in the Russian Federation have prepared an article, which covers the latest evidence based policy recommendations on the treatment and care of patients with drug-resistant TB.

Dr Melita Vujnovic

WHO Representative to the Russian Federation

REFERENCES:Based on the World Health Organization publications
KEYWORDS:

WHO: tb control in the european region. Operational tb research

FOR CORRESPONDENCE: 

NON-VIROLOGICAL LABORATORY MARKERS OF COVID‑19

Article 2.Page 12.
ARTICLE TITLE:

NON-VIROLOGICAL LABORATORY MARKERS OF COVID‑19

DOI: 10.7868/S2587667820030024

AUTORS:

Abdullaev R.Yu.1, Komissarova O.G.1,2

1 Central TB Research Institute, Moscow, Russia

2 Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 21.04.2020

The review provides literature data on specific changes in clinical and biochemical parameters of blood, as well as hemostatic and fibrinolytic systems in patients with COVID‑19 disease caused by novel coronavirus SARS-CoV‑2. It was shown that the changes in clinical and biochemical parameters of blood, as well as hemostatic and fibrinolytic systems in COVID‑19 patients have specific features and are strongly associated with severity of the disease. Lymphopenia and thrombocytopenia are most common for this category of patients. As for biochemical parameters, elevated CRP and ferritin levels along with reduced albumin levels are often detected. We should note that in one third of patients with severe COVID‑19 disease the activity of liver enzymes (ALT, AST) is increasing. The elevated concentration of D-dimer in blood plasma is typical for hemostatic and fibrinolytic systems.

REFERENCES:
  1. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, vol. 395, pp. 507–153.
  2. Chen H., Guo J., Wang C. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID‑19 infection in nine pregnant women: a retrospective review of medical records. Lancet, 2020, DOI: 10.1016/S0140-6736(20)30360-3
  3. Guan W.J., Ni Z.Y., Hu Y. et al. China Medical Treatment Expert Group for COVID‑19. Clinical haracteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, DOI: 10.1056/NEJMoa2002032
  4. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, pp. 497–506.
  5. Lippi G., Plebani M. Laboratory abnormalities in patients with COVID‑2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM), 2020, DOI: https://doi.org/10.1515/cclm‑202-0198
  6. Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID‑19) infections: A meta-analysis. Clin. Chem. Acta, 2020, vol. 506, pp. 145–148, DOI: 10.1016/j.cca.2020.03.022
  7. Lippi G., Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease
  8. Hematology Transfusion and Cell Therapy, 2020, DOI: 10.1016/j.htct.2020.03.001
  9. Liu W., Li H. COVID‑19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv, 2020. Preprint. https://doi.org/10.26434/chemrxiv.11938173.v
  10. Liu Y., Yang Y., Zhang C., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China. Life Sci., 2020, DOI: 10.1007/s11427-020-1643-8
  11. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020., DOI: 10.1111/jth.14768
  12. Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost., 2020, DOI: 10.1111/jth.14817
  13. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J. Am. Med. Assoc., 2020, DOI: 10.1001/jama.2020.1585
  14. Wang X.F., Yuan J., Zheng Y.J. et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Zhonghua Er Ke Za Zhi, 2020, vol. 58, p. E008.
  15. Zhang J.J., Dong X., Cao Y.Y. et al. Clinical characteristics of 140 patients infected by SARS-CoV‑2 in Wuhan, China. Allergy, 2020, DOI: 10.1111/all.14238
KEYWORDS:

COVID‑19, lymphopenia, thrombocytopenia, CRP, ferritin, D-dimer.

FOR CORRESPONDENCE:

Central ТВ Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Rizvan Yu. Abdullaev, Doctor of Medical Sciences, Professor, Leading Researcher, Department

of Pathomorphology, Cell Biology and Biochemistry, Head of Biochemistry Laboratory

Tel.: +7 (903) 226-81-22

E-mail: rizvan0403@yandex.ru

Oksana G. Komissarova, Doctor of Medical Sciences, Deputy Director for Research and Treatment,

Central TB Research Institute; Professor of Phthisiology Department, Medical Faculty, Russian National

Research Medical University named after N.I. Pirogov

Tel.: +7 (499) 785-90-19

Е-mail: oksana.komissarova.72@mail.ru

PULMONARY TUBERCULOSIS AND THE THYROID GLAND

Article 3.Page 17.
ARTICLE TITLE:

PULMONARY TUBERCULOSIS AND THE THYROID GLAND

DOI: 10.7868/S2587667820030036

AUTORS:

Polyakova A.S., Bagdasaryan T.R., Romanov V.V., Ergeshov A.E.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 18.05.2020

Tuberculosis (TB) is one of the global challenges facing humanity. Every year millions of people fall ill with TB, and about one million die from TB. Treatment effectiveness remains low due to drug resistance of mycobacteria, and due to comorbidities affecting other organs or systems, which often complicates the disease course. The aim of our literature review is to highlight the influence of the thyroid gland on the course of TB, and the influence of TB on the thyroid function.

The research was conducted under scientific theme 0515-2019-0015 “Modern approaches to diagnosis, epidemiology and treatment of drug resistant pulmonary TB, including TB associated with HIV infection or diabetes mellitus”.

REFERENCES:
  1. Balybin E.S. The immunomodulatory role of endogenous thyroid hormones in mycobacterioses. Problems of Tuberculosis, 1995, no. 2, pp. 37–39. (In Russ.)
  2. German A.O. The thyroid functional activity, the pituitary thyrotropic function, and the cortisol level in patients with newly diagnosed pulmonary TB depending on clinical forms. Bukovinsky medichny visnik, 2013, vol. 17, no. 3 (67), part 2, pp. 6–7. (In Ukr.)
  3. German A.O. The functional state of the thyroid gland in pulmonary TB: the status of the issue. Bukovinsky medichny visnik, 2012, no. 3, pp. 132–135. (In Ukr.)
  4. Global tuberculosis report 2018. WHO, 2018, pp. 1–2. (In Russ.) https://www.who.int/tb/publications/global_report/ru/
  5. Godes Yu.E. The study of the iodine-absorbing function of the thyroid gland in patients with mild forms of pulmonary tuberculosis. Problems of Tuberculosis, 1976, no. 4, pp. 74–78. (In Russ.)
  6. Denisov I.N., Shevchenko Yu.L. Clinical recommendations. Moscow, Geotar-Media, 2004, pp. 309–325. (In Russ.)
  7. Dzyubinskaya T.K. The course of TB under different functional states of the thyroid gland (hyperthyroidism and hypothyroidism). Problemy profilaktiki i lecheniya tuberkulyoza, Kharkov Scientific Medical Society. Kharkov, 1957, issue 8, pp. 96–102. (In Russ.)
  8. Dzyubinskaya T.K. The thyroid gland and TB. Abstract of a Thesis for a Doctor’s degree in Medicine: 14.00.26. Kharkov, 1966, 36 p. (In Russ.)
  9. Egorova I.L. Thyroid hormones and their interaction with the immune system in pulmonary TB with concomitant diabetes mellitus. The proceedings of the 4th (14th) congress of the Scientific and Medical Association of Phthisiologists. Yoshkar-Ola, 1999, p. 228. (In Russ.)
  10. Egorova I.L. Hormone homeostasis in experimental pulmonary TB. Problems of Tuberculosis, 1994, no. 1, pp. 38–40. (In Russ.)
  11. Kalankhodzhaev A.A. Clinical signs and treatment of TB with concomitant pathology of the thyroid. Problems of Tuberculosis, 1978, no. 8, pp. 27–31. (In Russ.)
  12. Korovkin V.S. Pulmonary TB in patients with diabetes mellitus. Mn., Nauka i tekhnika, 1985, 191 p. (In Russ.)
  13. Kucher V.A. The dynamics of thyroid hormones in pulmonary TB. Tuberculosis, Kiev, 1990, issue 22, 49–51. (In Russ.)
  14. Maskeev K.M. The functional state of the pituitarythyroid system in pulmonary TB. Zdravookhranenie Kazakhstana, 1983, no. 3, pp. 29–31. (In Russ.)
  15. Matveeva S.L. Clinical features and TB treatment outcomes in patients with thyroid pathology. Tuberculyoz. Legenevi khvoroby. VIL-infektsia, 2011, no. 2 (05), pp. 39–44. (In Russ.)
  16. Matveeva S.L. The result of a comprehensive study of thyroid functions in patients with chronic destructive pulmonary TB. Endokrinologu ot drugikh spetsialistov, 2009, no. 2, pp. 36–40. (In Russ.)
  17. Pirogov A.V. The hormonal activity of the thyroid gland in pulmonary TB patients. Problems of Tuberculosis, 1978, no. 6, pp. 31–34. (In Russ.)
  18. Provotorov V.M. Thyroid hormones and non-thyroid pathology. Russian Medical Journal, 2002, no. 5, 30–33. (In Russ.)
  19. Radionuclide diagnosis for practitioners. Ed. By Yu.B. Lishmanov, V.I. Chernov. Tomsk, STT, 2004, 394 p. (In Russ.)
  20. Sillastu Kh.A. Thyroid hormones in the pathogenesis of gland tuberculosis. Abstract of a Thesis for a Doctor’s degree in Medicine: 14.00.26. Tartu, 1974, 68 p. (In Russ.)
  21. Sirenko I.A. A hormonal shift in adolescents in the initial stage of TB infection. Problems of Tuberculosis, 1990, no. 6, pp. 32–35. (In Russ.)
  22. Tatarinova N.V. The functional state of the thyroid gland in tuberculosis. Abstract of a Thesis for a Candidate’s degree in Medicine: 14.00.26. Moscow, 1959, 23 p. (In Russ.)
  23. Todoriko L.D. The role of thyroid hormones and cortisol in the development of anaemic syndrome in elderly patients with chronic obstructive pulmonary disease. The proceedings of the 1st congress of therapeutists of Zabaikalsky Krai. Chita, 2013, pp. 71–75. (In Russ.)
  24. Todoriko L.D., Herman A.O. Clinical features of newly diagnosed pulmonary tuberculosis depending on the type of functional activity of the thyroid gland. Aktualnaya infektologia, 2015, no. 2, p. 7. (In Russ.)
  25. Turupanova N.R. The functional state of the thyroid gland in pulmonary TB patients. Sov. meditsina, 1961, 10, pp. 23–29. (In Russ.)
  26. Uvarova O.A. Histological and histochemical reactions of some endocrine glands in pulmonary TB in humans. Problems of Tuberculosis, 1963, no. 6, pp. 64–72. (In Russ.)
  27. Cherenko S.O. The correlation between the clinical course of pulmonary TB, the thyroid function, and some cytokines. Ukr. pulmonol. zh., 2011, no. 2, pp. 35–37. (In Russ.)
  28. The epidemic situation of TB in the Russian Federation in 2018, pp. 1–4, 12. (In Russ.)
  29. Callas G., Adkisson V.T. The effects of desiccated thyroid on the rat lung. Anat. Rec., 1980, vol. 197 (3), 331–337.
  30. Crisp A.J., Tutt S.M., McGregor K.H., Hainsworth R. The effects of changes in left ventricular pressure on respiratory activity in anesthetized dogs. Q. J. Exp. Physiol., 1989, vol. 74, pp. 291–300.
  31. Frodsham A.J., Hill A.V.S. Genetic of infectious disease. Hum. Mol. Genet., 2004, vol. 13, rev. issue 2, 187–194.
  32. Hein G. Handbuch der Tuberckulose. Stuttgart, 1964, vol. 4, 885 p.
  33. Henley W.N., Bellush L.L., Tressler M. Bulbospinal serotonergic activity during changes in thyroid state. Can. J. Pharmacol., 1998, vol. 76, pp. 1120–1131.
  34. Junod A. Metabolism, productions and release of hormones and mediators in the lung. Amer. Rev. Resp. Dis., 1975, vol. 112, no. 1, pp. 93–108.
  35. Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J. Endocrinol. Invest., 2004, vol. 27, no. 4, pp. 380–386.
  36. Kessler Saiz P., Jareno Chaumel J., Pascual Cuesta Т. et al. Asthma and hyperthyroidism. Rev. Clin. Esp., 1989, vol. 185, no. 9, pp. 478–479.
  37. Ormerod L.P. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br. Med. Bull., 2005, vol. 73–74, pp. 17–24.
  38. Podlaska M., Chelminska M., Sworczalc K. Respiratory disorders in thyroid pathology. Wiad. Lek., 2003, vol. 56, no. 9, pp. 468–474.
  39. Smith D.M. Thyroid hormone binding to adult rat alveolar type 2 cells. An autoradiografic study. Exp. Lung Res., 1983, vol. 5, no. 2, pp. 141–153.
  40. Tulea E., Schneider F., Schneider F., Petriou A. The metabolic and functional effects of thyroid hormone excess in rats. Physiologie, 1979, vol. 16, pp. 37–40.
  41. Upadhyaya L., Agrawal J.K., Dubey G.P. Effect of L-thyroxine and carbimazole on blood levels of biogenic amines in rat. Exp. Clin. Endocrinol., 1993, vol. 101, no. 5, pp. 307–310.
KEYWORDS:

tuberculosis, MDR, XDR, thyroid gland.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Angela S. Polyakova, Junior Researcher, Phthisiology Department

Tel.: +7 (963) 927‑61‑43

E-mail: angelamdid@yandex.ru

Tatevik R. Bagdasaryan, Candidate of Medical Sciences, Head, Therapeutic Unit no. 1

Tel.: +7 (499) 169‑99‑68

E-mail: norair04@mail.ru

Vladimir V. Romanov, Doctor of Medical Sciences, Head, Phthisiology Department

Tel.: +7 (499) 748‑30‑26

E-mail: romanov-vladimir-vik@mail.ru

Atadzhan E. Ergeshov, Doctor of Medical Sciences, Professor, Director

Tel.: +7 (499) 785‑90‑19

E-mail: cniit@ctri.ru

PREDICTORS OF UNFAVOURABLE TREATMENT OUTCOME IN TB PATIENTS RECEIVING TREATMENT REGIMENS FOR SUSCEPTIBLE TUBERCULOSIS

Article 4.Page 24.
ARTICLE TITLE:

PREDICTORS OF UNFAVOURABLE TREATMENT OUTCOME IN TB PATIENTS RECEIVING TREATMENT REGIMENS FOR SUSCEPTIBLE TUBERCULOSIS

DOI: 10.7868/S2587667820030048

AUTORS:

Saenko S.S.1, Sterlikov S.A.2, Rusakova L.I.3, Lekhleider M.V.4, Pirogova N.D.5, Surnacheva I.F.6,

Gudenkov M.A.7, Svicharskaya A.K.8, Podgainaya O.A.9, Kononenko Yu.S.10, Novikova T.V.11,

Yukhnova E.A.12, Frolov E.G.13, Gromov A.V.14, Gaevaya I.S.15

1 Regional Clinical Center of Phthisiopulmonology, Rostov-on-Don, Russia

2 Central Research Institute for Health Organization and Informatics, Moscow, Russia

3 Central TB Research Institute, Moscow, Russia

4 Chelyabinsk Regional Clinical TB Dispensary, Chelyabinsk, Russia

5 Regional TB Dispensary, Tyumen, Russia

6 Tula Regional TB Dispensary no. 1, Tula Region, Russia

7 Smolensk Regional TB Clinical Dispensary, Smolensk, Russia

8 Sevastopol TB Dispensary, Sevastopol, Russia

9 Crimean Republican Clinical Centre of Phthisiology and Pulmonology, Simferopol, Russia

10 Republican TB Dispensary, Petrozavodsk, Russia

11 Penza Regional TB Hospital, Penza, Russia

12 Novgorod Clinical Specialized Centre of Phthisiopulmonology, Veliky Novgorod, Russia

13 Moscow Regional TB Dispensary, Moscow, Russia

14 Kamchatka Krai TB Dispensary, Petropavlovsk-Kamchatsky, Russia

15 Amur Regional TB Dispensary, Blagoveshchensk, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 18.05.2020

Objective: To study the predictors of unfavourable treatment outcomes (death, treatment failure, default) in TB patients with preserved (or presumed) sensitivity to rifampicin. Materials and methods: A multicentre retrospective cohort study of 8,099 TB patients with preserved (or presumed) sensitivity to rifampicin registered in 2016. The following factors were evaluated: history of previous treatment (treatment failure or default), gender, age, place of residence, HIV status, microscopy results, lung cavities, mono/polyresistance before treatment. We conducted one- and multiple-factor analysis considering adjusted odds ratio (aOR). Results. The predictors of death were HIV infection (aOR = 8.7), sputum positivity (aOR = 2.4), default from previous treatment (aOR = 2.2), lung cavities (aOR = 1.7), age (aOR = 1.04 per life year), male gender (aOR = 1.3). Previous treatment failure, rural residence or mono/polyresistance did not influence the outcome. The

predictors of treatment failure were default from previous treatment (aOR = 3.9), previous treatment failure (aOR = 2.1), lung cavities (aOR = 2.1), mono/polyresistance (aOR = 1.9), male gender (aOR = 1.7), sputum positivity (aOR = 1.3), rural residence (aOR = 1.4). HIV status or age did not influence the outcome. The predictors of treatment default were default from previous treatment (aOR = 5.8), previous treatment failure (aOR = 2.2), HIV infection (aOR = 1.9), lung cavities (aOR = 1.9), male gender (aOR = 1.9), sputum positivity. Age, rural residence or mono/polyresistance did not influence the outcome. Conclusion. The obtained data allow to assess the risk of unfavourable treatment outcome in each case. The most important predictor is default from treatment, which should be considered as a criterion for enrolling patients in psychosocial support programmes.

REFERENCES:
  1. Bogorodskaya E.M., Sterlikov S.A. The main course treatment outcomes in pulmonary TB patients registered in 2007. Tuberculosis and Lung Diseases, 2010, no. 11, pp. 30–37. (In Russ.)
  2. Clinical recommendations. Tuberculosis in adults. ID: КР16/1. URL: http://cr.rosminzdrav.ru/#!/recomend/943 (In Russ.)
  3. Clinical recommendations. Tuberculosis in children. ID: КР507/1. URL: http://cr.rosminzdrav.ru/#!/recomend/359 (In Russ.)
  4. Order No. 50 of the Ministry of Health of the Russian Federation of 13.02.2004 on the introduction of a system for data collection using quarterly cohort analysis. Tver, Triada, 2004, 48 p. (In Russ.)
  5. Saenko S.S., Sterlikov S.A., Rusakova L.I., Gaevaya I.S., Nagibina L.A., Frolov E.G., Yukhnova E.A., Novikova T.V., Kononenko Yu.S., Podgainaya O.A., Svicharskaya A.K., Gudenkov M.A., Surnacheva I.F., Pirogova N.D., Lekhleider M.V. The predictors of lethal outcomes in patients with HIV-associated TB. Current problems of health care and medical statistics, 2020, no. 1, pp. 314–334, DOI: 10.24411/2312‑2935‑2020‑00022 (In Russ.)
  6. Sterlikov S.A., Galkin V.B., Rusakova L.I., Ponomarev S.B., Gordina A.V. Treatment outcomes in TB patients in 2018. Current problems of health care and medical statistics, 2019, no. 3, pp. 28–68, DOI: 10.24411/2312‑2935‑2019‑10054 (In Russ.)
  7. Aibana O., Slavuckij A., Bachmaha M., Krasiuk V., Rybak N., Flanigan T.P., Petrenko V., Murray M.B. Patient predictors of poor drug sensitive tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859782/, DOI: 10.12688/f1000research.12687.3
  8. Amoran O.E. Determinants of treatment failure among tuberculosis patients on directly observed therapy in rural primary health care centres in Ogun State, Nigeria. Journal of Primary Health Care: Open Access, 2011, no. 1, issue 1, DOI: 10.4172/2167-1079.1000104
  9. Basa S., Venkatesh S. Study on default and its factors associated among tuberculosis patients treated under DOTS in Mayurbhanj District, Odisha. Journal of Health Research and Reviews in Developing Countries, 2015, vol. 2, pp. 25–28.
  10. Belilovsky E.M., Borisov S.E., Cook E.F., Shaykevichc S., Jakubowiak W.M., Kourbatova E.V. Treatment interruptions among patients with tuberculosis in Russian TB hospitals. International Journal of Infectious Diseases, 2010, vol. 14, issue 8, pp. 698–703, DOI: 10.1016/j.ijid.2010.03.001
  11. Dale K., Tay E., Trauer J.M., Trevan P., Denholm J. Gender differences in tuberculosis diagnosis, treatment and outcomes in Victoria, Australia, 2002–2015. The International Journal of Tuberculosis and Lung Disease, 2017, vol. 21, no. 12, pp. 1264–1271, DOI: 10.5588/ijtld.17.0338
  12. Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014), WHO/HTM/TB/2013.2. Mode of access: https://www.who.int/tb/publications/definitions/en/ (Date of referral: 22.01.2020).
  13. Diallo A., Dahourou D.L., Dah T.T.E., Tassembedo S., Sawadogo R., Meda N. Factors associated with tuberculosis treatment failure in the Central East Health region of Burkina Faso. The Pan African Medical Journal, 2018, vol. 30, p. 293, DOI: 10.11604/pamj.2018.30.293.15074
  14. El-Shabrawya M., El-Shafei D. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014. Egyptian Journal of Chest Diseases and Tuberculosis, 2017, vol. 66, issue 1, pp. 145–152, DOI: 10.1016/j.ejcdt.2015.11.002
  15. Garrido M.S., Penna M.L., Perez-Porcuna T.M., Souza A.B., Marreiro L.S., Albuquerque B.C., Martínez-Espinosa F.E., Bhrer-Sékula S. Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: A case control study. PLoS One, 2012, no. 7 (6), DOI: 10.1371/journal.pone.0039134
  16. Global TB Report 2019. WHO/CDS/TB/2019.15. ISBN 978‑92‑4‑156571‑4
  17. Habib S., Zaidi S.M.A., Jamal W., Zafar I., Kazmi T., Yasir M. Predictors of treatment failure among pulmonary tuberculosis patients in Pakistan. European Respiratory Journal, 2019, vol. 54, issue suppl. 63, DOI: 10.1183/13993003.congress‑2019.PA2950
  18. Hameed S., Zuberi F.F., Hussain S., Ali S.K. Risk factors for mortality among inpatients with smear positive pulmonary tuberculosis. Pakistan Journal of Medical Sciences, 2019, no. 35(5), pp. 1361–1365, DOI: 10.12669/pjms.35.5.919
  19. Holden I.K., Lillebaek T., Seersholm N., Andersen P.H., Wejse C., Johansen I.S. Predictors for pulmonary tuberculosis treatment outcome in Denmark 2009–2014. Scientific Reports, 2019, DOI: 10.1038/s41598‑019‑49439‑9
  20. Hood G., Trieu L., Ahuja S.D. Mortality among tuberculosis patients in New York City. The International Journal of Tuberculosis and Lung Diseases, 2019, vol. 23, no. 2, pp. 252–259. DOI: 10.5588/ijtld.18.0305
  21. Kigozi G., Heunis C., Chikobvu P., Botha S., Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa. International Journal of Infectious Diseases, 2017, vol. 54, pp. 95–102, DOI: 10.1016/j.ijid.2016.11.407
  22. Kliiman K. Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Diseases, 2010, no. 14 (4), pp. 454–463.
  23. Morsy A.M., Zaher H.H., Hassan M.H., Shouman A. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. Eastern Mediterranean Health Journal, 2003, no. 9 (4), pp. 689–701.
  24. Namukwaya E., Nakwagala F.N., Mulekya F., Mayanja-Kizza H., Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. African Health Sciences, 2011, no. 11, suppl. 1, pp. 105–111, DOI: 10.4314/ahs.v11i3.70079
  25. Sauer C.M., Sasson D., Paik K.E., McCague N., Celi L.A., Fernández I.S., Illigens M.W. Feature selection and prediction of treatment failure in tuberculosis. PLoS One, 2018, no. 13(11), p. e0207491, DOI: 10.1371/journal. pone.0207491
  26. Slama K., Tachfouti N., Obtel M., Nejjari C. Factors associated with treatment default by tuberculosis patients in Fez, Morocco. Eastern Mediterranean Health Journal, 2013, no. 19 (8), pp. 687–693.
  27. Sylvère T.A. Default time from tuberculosis treatment in the southern republic of Benin using mixture cure model for survival analysis. Biometrics & Biostatistics International Journal, 2015, no. 2 (5), pp. 118–129, DOI: 10.15406/bbij.2015.02.00039
KEYWORDS:

TB, predictors of treatment failure, predictors of death, predictors of treatment default, prediction of treatment outcomes, selection criteria for psychosocial support.

FOR CORRESPONDENCE:

Regional Clinical Center of Phthisiopulmonology

24, Orskaya St., 344065, Rostov-on-Don, Russia

Sergey S. Saenko, Head, Organization and Methodology Department

Tel.: +7 (938) 110‑77‑77

E-mail: saenkosergey@yandex.ru

Central Research Institute for Health Organization and Informatics

11, Dobrolyubov St., 127254, Moscow, Russia

Sergey A. Sterlikov, Doctor of Medical Sciences, Deputy Director, Federal TB Monitoring Center

in the Russian Federation, Programme Monitoring

Tel.: +7 (925) 507‑82‑21

Е-mail: sterlikov@list.ru

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Larisa I. Rusakova, Doctor of Medical Sciences, Head, Research Administration Department

Tel.: +7 (926) 584‑17‑79

Е-mail: larisa.rusakova@mail.ru

Chelyabinsk Regional Clinical TB Dispensary

38, Vorovsky St., 454020, Chelyabinsk, Russia

Marina V. Lekhleider, Candidate of Medical Sciences, Chief Physician

Tel.: +7 (3512) 32‑15‑37

Е-mail: info@chokptd74.ru

Regional TB Dispensary

2A, Kurortnaya St., 625017, Tyumen, Russia

Natalya D. Pirogova, Chief Physician

Tel.: +7 (3452) 43‑35‑89

Е-mail: pirogova-ishim@yandex.ru

Tula Regional TB Dispensary no. 1

v. Petelino, Ilyinka, Leninsky Raion, 301105, Tula Region, Russia

Irina F. Surnacheva, Methodist Doctor

Tel.: +7 (910) 551‑05‑43

Е-mail: irina.surnacheva@tularegion.org

Smolensk Regional TB Clinical Dispensary

10, Kommunalnaya St., 214018, Smolensk, Russia

Mikhail A. Gudenkov, Chief Physician

Tel.: +7 (910) 726‑62‑20

Е-mail: gudmik1@mail.ru

Sevastopol TB Dispensary

45, Gotskaya St., 299021, Sevastopol, Russia

Anna K. Svicharskaya, Deputy Chief Physician

Tel.: +7 (9978) 730‑41‑76

Е-mail: antcha-s@yandex.ru

Crimean Republican Clinical Centre of Phthisiology and Pulmonology

34, Franko Blvd., 295034, Simferopol, Russia

Olesya A. Podgainaya, Head, Organization and Methodology Department

Tel.: +7 (978) 771‑87‑06

Е-mail: crimea_rtbd@mail.ru

Republican TB Dispensary

40, Lev Tolstoy St., 185003, Petrozavodsk, Russia

Julia S. Kononenko, Candidate of Medical Sciences, Chief Physician

Tel.: +7 (911) 404‑88‑42

Е-mail: yuliya.kononenko.1978@mail.ru

Penza Regional TB Hospital

62–12, Uritsky St., 440008, Penza, Russia

Tatyana V. Novikova, Phthisiologist

Tel. +7 (960) 312‑41‑67

Е-mail: novikovatv57@mail.ru

Novgorod Clinical Specialized Centre of Phthisiopulmonology

11, Parkovaya St., 173020, Veliky Novgorod, Russia

Evgeniya A. Yukhnova, Feldsher, Organization and Methodology Department

Tel.: +7 (8162) 63‑54‑36

Е-mail: omotub_nov@mail.ru

Moscow Regional TB Dispensary

11, Ploshchad Borby, 127005, Moscow, Russia

Evgeny G. Frolov, Deputy Chief Physician

Tel.: +7 (915) 460‑08‑44

Е-mail: odpp@mail.ru

Kamchatka Krai TB Dispensary

9, Ordzhonikidze St., 683024, Petropavlovsk-Kamchatsky, Russia

Andrey V. Gromov, Chief Physician

Tel.: +7 (4152) 26‑84‑75

Е-mail: gromov@tubkam.ru

Amur Regional TB Dispensary

5, Liteinaya St., 675005, Blagoveshchensk, Amur Region, Russia

Irina S. Gaevaya, Deputy Chief Physician

Tel.: +7 (914) 579‑72‑49

Е-mail: aoptd@amurzdrav.ru

THE MORPHOLOGY OF HEALING PROCESSES IN THE LUNG TISSUE OF PATIENTS WITH DRUG RESISTANT PULMONARY TB AFTER PREOPERATIVE INTRAVENOUS LASER BLOOD IRRADIATION

Article 5.Page 35.
ARTICLE TITLE:

THE MORPHOLOGY OF HEALING PROCESSES IN THE LUNG TISSUE OF PATIENTS WITH DRUG RESISTANT PULMONARY TB AFTER PREOPERATIVE INTRAVENOUS LASER BLOOD IRRADIATION

DOI: 10.7868/S258766782003005X

AUTORS:

Lepekha L.N., Aliev V.K., Krasnikova E.V., Bagirov M.A.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 20.04.2020

The relevance of the study is justified by the necessity to provide scientific and practical rationale for wider application of intravenous laser blood irradiation (ILBI) in the preoperative care of patients with drug-resistant fibrocavernous pulmonary TB. Objective: Detection and morphological description of healing processes in resection samples from patients with fibrocavernous pulmonary TB, who received ILBI before surgery. Materials and methods. We carried out a comparative morphological study of resection samples from 22 patients with drug-resistant fibrocavernous TB, who received ILBI with gallium arsenide, 14 sessions, 8 min each, before surgery, and 24 patients with similar pathology without preoperative endovascular exposure (comparison group). Results. ILBI triggered the activation of angiogenesis, the inflow of lymphocytes and macrophages in the perifocal inflammation area. These processes facilitated involution and encapsulation of small and larger caseation foci, fibrozation and hyalinization of lymphohematogenous and bronchogenic dissemination foci. Such processes were not observed in the comparison group.

The study was conducted under research topic no. 0515‑2019‑0017 “The development of methods of surgical treatment for disseminated pulmonary TB and bones and joints TB”.

REFERENCES:
  1. Ariel B.M. Pathological anatomy and pathogenesis of tuberculosis. In: Guidelines on pulmonary and extrapulmonary tuberculosis. Ed. by Yu.N. Levashev, Yu.M. Repin. St. Petersburg, ELBI-SPb, 2006, pp. 67–(In Russ.)
  2. Bagirov М.A., Dobkin V.G., Kuiliyev E.M., Bondarev G.B., Ertuganov O.F. The effectiveness of different type laser application in the surgical treatment of pulmonary TB patients. Problems of Tuberculosis, 1992, no. 1/2, pp. 53–55. (In Russ.)
  3. Bril G.E. Semiconductor laser irradiation stimulates angiogenesis. Lazernaya meditsina, 2004, vol. 8, issue 3, p. 157. (In Russ.)
  4. Vasilyeva I.A., Samoilova A.G., Zimina V.N., Komissarova O.G., Bagdasaryan T.R., Lovacheva O.V. Treatment of tuberculosis: past experience, current state and prospectives. Tuberculosis and Lung Diseases, 2013, no. 5, pp. 31–37. (In Russ.)
  5. Dobkin V.G. New advances in laser medicine. St. Petersburg, 1993, pp. 70–71. (In Russ.)
  6. Dobkin V.G., Bagirov M.A., Bondarev G.B., Sadovnikova S.S. Different type laser application in the complex treatment of pulmonary TB patients. Problems of Tuberculosis, 1996, no. 6, pp. 54–57. (In Russ.)
  7. Erokhin V.V., Gedymin L.E., Zemskova Z.S., Lepekha L.N., Parkhomenko Yu.G., Ziuzia Yu.R., Burtseva S.A., Dyukanova M. Ya., Fligel D.M. Postmortem diagnosis of the major forms of tuberculosis (according to autopsy data). Problems of Tuberculosis and Lung Diseases, 2008, vol. 85, no. 7–8, pp. 45–64. (In Russ.)
  8. Ziuzia Yu.R., Lepekha L.N., Gedymin L.E., Burtseva S.A., Erokhin V.V. The tissue and cellular reactions of the lung in drug-resistant tuberculosis. Tuberculosis and Lung Diseases, 2004, no. 8, pp. 53–56. (In Russ.)
  9. Krasnikova E.V., Aliev V.K., Lepekha L.N., Sadovnikova S.S., Karpov S.S., Prokhodtsov D.N., Bagirov M.A. Intraoperative innovative technologies and intravenous laser blood irradiation in the combination treatment of bilateral drug-resistant destructive pulmonary tuberculosis. Vrach, no. 11, pp. 43–48. (In Russ.)
  10. Litvinov V.I., Dobkin V.G., Lebedev K.M., Lovacheva O.V. Impact of low-energy laser irradiation on the immunological nonspecific responsiveness in patients with tuberculosis. Problems of Tuberculosis, 1997, no. 4, pp. 58–60. (In Russ.)
  11. Rusakova L.I., Dobkin V.G., Ovsyankina E.S. Effectiveness of blood laser irradiation in the treatment of advanced pulmonary TB in adolescents. Problems of Tuberculosis, 2002, no. 8, pp. 16–18. (In Russ.)
  12. Eshankhanov M.E., Khodzhaeva M.E., Kozarez M.I., Aliev Sh.T. Possibilities and prospects of intravascular irradiation of blood by helium-neon laser in patients with pulmonary tuberculosis. Problems of Tuberculosis, 1993, no. 2, pp. 27–29. (In Russ.)
  13. Aliev V., Sadovnikova S., Krasnikova E., Lepekha L., Bagirov M. Recovery process in lung tissue patients with XDR tuberculosis after preoperative intravenous laser blood irradiation. European Respiratory Journal, 2019, vol. 54, issue 63, DOI: 10.1183/13993003.congress‑2019. PA2213
  14. Bagirov М., Aliev V., Sadovnikova S., Krasnikova E., Prokhodtsov D. Intravenous laser blood irradiation in preoperative preparation for patients with XDR tuberculosis. European Respiratory Journal, 2018, vol. 52, issue 62, p. PA1738.
  15. Migliori G.B., Sotgiu G., Gandhi N.R., Falzon D., DeRiemer K., Centis R, Hollm-Delgado M.-G., Palmero D., Pérez-Guzmán C., Vargas M.H., D’Ambrosio L., Spanevello A., Bauer M., Chan E.D., Schaaf H.S., Keshavjee S.,Holtz T.H., Menzies D. On behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data metaanalysis. European Respiratory Journal, 2013, no. 42, pp. 169–179, DOI: 10.1183/09031936.00136312
  16. Takeda S., Maeda H., Hayakawa M., Sawabata N., Maekura R. Current surgical intervention for pulmonary tuberculosis. The Annals of thoracic surgery, 2005, vol. 79, issue 3, pp. 959–963.
KEYWORDS:

drug-resistant fibrocavernous pulmonary TB, intravenous laser blood irradiation, histology.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Larisa N. Lepekha, Doctor of Biological Sciences, Professor, Head, Department of Pathomorphology,

Cell Biology and Biochemistry

Tel.: +7 (499) 785‑91‑79

Е-mail: lep3@yandex.ru

Vilayat K. Aliev, Candidate of Medical Sciences, Junior Researcher, Surgery Department

Tel.: +7 (499) 785‑91‑96

Е-mail: vilaliev@gmail.com

Elena V. Krasnikova, Doctor of Medical Sciences, Senior Researcher, Surgery Department

Tel.: +7 (499) 785‑91‑96

Е-mail: el.krasn@gmail.com

Mamed A. Bagirov, Doctor of Medical Sciences, Professor, Head, Surgery Department

Tel.: +7 (499) 785‑91‑96

Е-mail: bagirov60@gmail.com

ON THE QUESTION OF EFFECTIVENESS AND SAFETY OF BEDAQUILINE-CONTAINING REGIMENS IN THE TREATMENT OF PULMONARY TB WITH MULTIPLE OR EXTENSIVE DRUG RESISTANCE IN SENIOR CHILDREN AND ADOLESCENTS

Article 6.Page 43.
ARTICLE TITLE:

ON THE QUESTION OF EFFECTIVENESS AND SAFETY OF BEDAQUILINE-CONTAINING REGIMENS IN THE TREATMENT OF PULMONARY TB WITH MULTIPLE OR EXTENSIVE DRUG RESISTANCE IN SENIOR CHILDREN AND ADOLESCENTS

DOI: 10.7868/S2587667820030061

AUTORS:

Krushinskaya E.A., Panova L.V., Ovsyankina E.S.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 28.05.2020

Aim: to assess effectiveness and safety of bedaquiline (Bdq)-containing regimens in the treatment of pulmonary TB with multiple/extensive drug resistance (MDR/XDR TB) in senior children and adolescents. Materials and methods. A cohort prospective study of 33 patients aged 14–17 with pulmonary MDR/XDR TB was carried out in 2015–2018. The informed consent to use Bdq was obtained from the parents. Bdq tolerance was monitored by ECG with QT interval assessment (the normal interval for children aged 0–18 was 0.36–0.44 sec): weekly during the 1st month of treatment, monthly afterwards. Results. In 13 out of 33 cases (39.4%) Bdq-containing regimens were administered. The criteria for Bdq administration were as follows: impossibility to form an effective treatment regimen based on drug susceptibility testing (DST) and/or impossibility to form a treatment regimen due to the development of intractable adverse reactions. In 7 out of 13 cases Bdq was administered due to DST results, in 3 cases – due to the development of adverse reactions to major drugs, and in 3 cases – due to the both factors. In 8 (61.5%) out of 13 cases Bdq was used in shortened 12-month regimens. In 9 (69.3%) out of 13 cases administration of two Bdq courses was justified. In 11 (84.6%) out of 13 cases good tolerance of Bdq-containing regimens was observed.

The article was prepared under research topic no. 0515‑2019‑0016 “Personalized approaches to pulmonary TB treatment in children and adolescents”.

REFERENCES:
  1. Clinical recommendations on childhood TB. Russian Society of phthisiatricians, 2020, pp. 21–25. (In Russ.)
  2. The normative parameters of ECG in children. Methodical recommendations. Institute of Postgraduate Education. Moscow, MEDPRAKTIKA-M, 2018, 17 p. (In Russ.)
  3. A method for determining the duration of chemotherapy of tuberculosis of respiratory organs with multiple and extensive drug resistance of MTB in children and adolescents. Patent for invention RU2680972, 01.03.2019. (In Russ.)
  4. The epidemic situation of childhood TB in Russia in 2018. (In Russ.) https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_deti.pdf
  5. Pipeline report 2019, Pediatric tuberculosis diagnosis, treatment, and prevention, htp://www.pipelinereport.org/
  6. WHO consolidated guidelines on drug-resistant tuberculosis treatment, https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TBtreatment/en/
KEYWORDS:

pulmonary TB, MDR/XDR TB, children and adolescents, bedaquiline, TB drug tolerance.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Ekaterina A. Krushinskaya, Junior Researcher, Child and Adolescent Department

Tel.: +7 (499) 785‑90‑05

Е-mail: detstvocniit@mail.ru

Ludmila V. Panova, Doctor of Medical Sciences, Leading Researcher, Child and Adolescent Department

Tel.: +7 (499) 785‑90‑05

Е-mail: detstvocniit@mail.ru 

Elena S. Ovsyankina, Doctor of Medical Sciences, Professor, Principal Researcher, Head of Child and Adolescent Department

Tel.: +7 (499) 785‑90‑05

Е-mail: detstvocniit@mail.ru

CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM RECOMMENDATIONS TO PRACTICE IN THE REPUBLIC OF TATARSTAN

Article 7.Page 49.
ARTICLE TITLE:

CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM RECOMMENDATIONS TO PRACTICE IN THE REPUBLIC OF TATARSTAN

DOI: 10.7868/S2587667820030073

AUTORS:

Vizel I.Yu.1, 2, Salakhova I.N.1, Shmelev E.I.2, Vizel А.А.1, 3, Vafina A.R.1, Shakirova G.R.1, 3, Dyakova E.V.3

1 Kazan State Medical University, Kazan, the Republic of Tatarstan, Russia

2 Central TB Research Institute, Moscow, Russia

3 Republican Clinical Hospital, Kazan, the Republic of Tatarstan, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 12.03.2020

COPD is a chronic irreversible disease. The treatment is targeted to slow the rate of lung function decline and preserve the quality of life. COPD phenotypes diverge, and approaches to treatment quickly improve. Therefore, it is important to monitor the situation in the healthcare practice. Aim: To evaluate clinical, laboratory and functional characteristics of COPD patients with different frequency of exacerbation and on different treatments. Materials: We studied 330 COPD patients (327 men and 3 women) aged 64,2 ± 0,47 (from 40 to 89) years, the median age was 64. The patients completed questionnaires, underwent spirometry. Prescribed treatment and treatment adherence were assessed. We stored and processed data using the SPSS‑18 software on Windows 10. Results: We referred 61.1% of patients to GOLD III–IV (GOLD 2007), and 78.2% – to D (GOLD 2017). The “frequent exacerbator” phenotype was reliably associated with declined FEV1 and high of mMRC and CAT scores. The share of COPD patients with more than two exacerbations per year and eosinophilia ≥ 300 · 109/l was 9.9%. Short-acting bronchodilators were prescribed to 86.4% of patients, as monotherapy – to 25.5% of them. The combination of IGCS-LABA was given to 54.2% of patients, duel combinations of long-acting bronchodilators – to 20.9%, and triple combinations – to 15.2%. IGCS were prescribed to COPD patients with the key adverse signs (frequent exacerbations, high scores of questionnaires, declined FEV1, eosinophilia ≥ 300 · 109/l). The administration of systemic glucocorticosteroids was only based on declined FEV1 and high scores. High treatment adherence was most common among patients with expressed COPD symptoms. Conclusion. In the Republic of Tatarstan pulmonologists observe patients with impaired spirometry functions, frequent exacerbations and expressed symptoms. The key treatments include short-acting bronchodilators and IGCS-LABA combinations. Treatment adherence is higher in patients with severe symptoms of COPD.

REFERENCES:
  1. Avdeev S.N. Pathologic physiology of exacerbations of chronic obstructive pulmonary disease. Messenger of Anesthesiology and Resuscitation, 2019, vol. 16, no. 2, pp. 75–82, DOI: 10.21292/2078‑5658‑2019‑16‑2‑75‑82. (In Russ.)
  2. The Russian Federation Ministry of Health; Russian Respiratory Society. Chronic obstructive pulmonary disease. Clinical recommendations. 2018. (In Russ.) Mode of access: http://cr.rosminzdrav.ru/#!/recomend/908
  3. Nasledov A.D. SPSS15: Professional statistical data analysis. St. Petersburg, Piter, 2008, 416 p. (In Russ.)
  4. Puxxedu E., Ora J., Calzetta L., Cazzola M. Progress and prospects for long-acting β2-agonists in the treatment of chronic obstructive pulmonary disease (COPD). Vestnik sovremennoi klinicheskoi mediciny. 2018, vol. 11, no. 1, pp. 78–79. (In Russ.)
  5. Fofanova T.V., Ageev F.T., Smirnova M.D., Svirida O.N., Kuzmina A.E., Tkhostov A.Sh., Nelyubina A.S. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension, 2014, no. 2, pp. 13–16. (In Russ.)
  6. Arkhipov V., Arkhipova D., Miravitlles M., Lazarev A., Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon Dis., 2017, vol. 12, pp. 3255–3262, DOI: 10.2147/COPD.S142997
  7. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. Available from: http://www.goldcopd.org/
  8. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med., 2010, vol. 182, no. 5, pp. 598–604.
  9. Izquierdo J.L., Miravitlles M., Esquinas C., Pé rez M., Calle M., Ló pez Campos J.L., Rodríguez González Moro J.M., Casanova C., Esteban C., de Lucas P. Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD Groups and GesEPOC clinical phenotypes. Arch. Bronconeumol., 2018, vol. 54, no. 11, pp. 559–567, DOI: 10.1016/j.arbres.2018.03.021
  10. Mä kelä M.J., Backer V., Hedegaard M., Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir. Med., 2013, vol. 107, no. 10, pp. 1481–1490, DOI: 10.1016/j.rmed.2013.04.005
  11. Vogelmeier C.F., Kostikas K., Fang J., Tian H., Jones B., Morgan C.L., Fogel R., Gutzwiller F.S., Cao H. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir. Res., 2019, vol. 20, no. 1, p. 178, DOI: 10.1186/s12931-019-1130-y
KEYWORDS:

chronic obstructive pulmonary disease, exacerbation, eosinophilia, treatment.

FOR CORRESPONDENCE:

Kazan State Medical University

49, Butlerov St., 420012, Kazan, Tatarstan, Russia

Irina Yu. Vizel, Doctor of Medical Sciences, Professor of Russian Academy of Natural Sciences, Docent, Phthisiopulmonology Department; Researcher at Central TB Research Institute

Tel.: +7 (917) 903‑91‑13

Е-mail: tatpulmo@mail.ru

Irina N. Salakhova, Postgraduate, Phthisiopulmonology Department

Tel.: +7 (937) 283‑32‑25

Е-mail: iboroznova@gmail.com

Adelya R. Vafina, Postgraduate, Phthisiopulmonology Department

Tel.: +7 (960) 054‑03‑64

Е-mail: adelyavafina@gmail.com

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Evgeny I. Shmelev, Doctor of Medical Sciences, Professor, Head, Department of Differential Diagnosis of TB and Extracorporal Treatments

Tel.: +7 (903) 192‑32‑74

Е-mail: eishmelev@mail.ru

Kazan State Medical University

49, Butlerov St., 420012, Kazan, Tatarstan, Russia

Republican Clinical Hospital

138, Orenburgsky trakt, 420064, Kazan, Tatarstan, Russia

Alexander A. Vizel, Doctor of Medical Sciences, Professor, Head, Phthisiopulmonology Department, Kazan State Medical University; Pulmonologist, Republican Clinical Hospital

Tel.: +7 (987) 296‑25‑99

Е-mail: lordara@inbox.ru

Gulnaz R. Shakirova, Candidate of Medical Sciences, Assistant, Phthisiopulmonology Department,

Kazan State Medical University; Pulmonologist, Republican Clinical Hospital

Tel.: +7 (917) 884‑30‑39

Е-mail: adeleashakirova@mail.ru

Republican Clinical Hospital

138, Orenburgsky trakt, 420064, Kazan, Tatarstan, Russia

Ekaterina V. Dyakova, Pulmonologist, Head, Pulmonology Department

Tel.: +7 (917) 266‑79‑93

Е-mail: vrkaty.dyakowa@yandex.ru

THE STANDARDS OF KNOWLEDGE OF THE INTERNATIONAL CONCEPTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Article 8.Page 58.
ARTICLE TITLE:

THE STANDARDS OF KNOWLEDGE OF THE INTERNATIONAL CONCEPTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

DOI: 10.7868/S2587667820030085

AUTORS:

Liverko I.V.1, Tashmetova G.T.2

1 Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology, Tashkent, Uzbekistan

2 Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan

DESCRIPTION OF ARTICLE:

Submitted as of 28.05.2020

COPD is one of the priority issues of the WHO Global Action Plan for the Prevention and Control of Non-Communicable Diseases, and the health systems should be oriented towards early detection and prevention of COPD [3]. Aim: To assess the proficiency of medical workers before postgraduate education in pulmonology. Materials and methods. We conducted an anonymous survey of 590 professionals including medical graduates, general practitioners, therapeutists and respiratory medicine specialists using questions, which were supposed to assess knowledge about the disease, its diagnosis, treatment, and prevention. Results. The assessment of professional competence in COPD diagnosis and treatment as per international recommendations revealed a low level of basic knowledge in all professionals, from medical graduates to general practitioners/therapeutists. We detected unsatisfactory knowledge of COPD diagnosis issues, which accounted for rapid progression of the disease and unfavourable outcomes.

REFERENCES:
  1. Aysanov Z.R., Chernyak A.V., Kalmanova E.N. Spirometry for diagnosis and therapeutic efficacy evaluation in chronic obstructive pulmonary disease in primary care. Pulmonologiya, 2014, no. 5, pp. 101–110. (In Russ.)
  2. Arkhipov V.V. A pharmacoeconomic approach to therapy of chronic obstructive pulmonary disease. Consilium Medicum, 2010, vol. 12, no. 3, pp. 85–86 (In Russ.)
  3. Vasilyeva O.S., Gushchina E.E., Kravchenko N.Yu. Chronic obstructive pulmonary disease caused by toxic aerosols. In: Regional aspects of innovative techniques in prevention, diagnosis, treatment, and rehabilitation of patients with occupational or production-related diseases of upper airways or lungs: Proceedings of the All-Russian Scientific and Practical Conference with International Participation. Veliky Novgorod, Borovichi, 2013, pp. 58–62. (In Russ.)
  4. Gambaryan M.G., Drapkina O.M. Chronic obstructive pulmonary disease and tobacco smoking: the principles and the ways of prevention (a review). Profilakticheskaya meditsina, 2017, no. 5, pp. 74–82. (In Russ.)
  5. Global strategy for the diagnosis, treatment and prevention of COPD (revised in 2014): translated from English. Ed. by A.S. Belevsky. Moscow, Russian Respiratory Society, 2015, 93 p. (In Russ.)
  6. Kotlyarov S.N. Spirometry screening in evaluation of chronic obstructive pulmonary disease at primary care. I.P. Pavlov Russian Medical Biological Herald, 2011, vol. 19 (1), pp. 91–95. (In Russ.)
  7. Litvinova I.V., Ovcharenko S.I. The diagnosis of chronic obstructive pulmonary disease in outpatient settings. Bolezni organov dykhaniya, 2004, no. 1, pp. 56–70. (In Russ.)
  8. Pulmonology: national guidelines. Ed. by A.G. Chuchalin. Moscow, 2009, 960 p. (In Russ.)
  9. Chuchalin A.G., Avdeev S.N., Gaydar E.N. et al. The role of almitrine in the treatment of respiratory failure in COPD patients. Pulmonologiya, 2006, no. 1, pp. 81–87. (In Russ.)
  10. Balter M.S. Chronic Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. J. Can. Respir., 2003, vol. 10, Suppl B, pp. 3B‑32B.
  11. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHHLBI/WHO workshop report. Last updated 2008.
  12. Ghan R., Radcliff T., Fish R. et al. Predictors of rehospitalisation and death after a severe exacerbation of COPD. Chest, 2007, vol. 132, no. 6, pp. 1748–1755.
KEYWORDS:

chronic obstructive pulmonary disease, diagnosis standards, treatment standards, early diagnosis, functional methods of study.

FOR CORRESPONDENCE:

Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology

1, Mazhlisy St., Shaikhontakhursky raion, 100086, Tashkent, Uzbekistan

Irina V. Liverko, Doctor of Medical Sciences, Deputy Director for Research and Innovation

Tel.: + (998 71) 278‑04‑70

Е-mail: liverco@yandex.ru

Tashkent Institute of Postgraduate Medical Education

51, Parkentskaya St., Mirzo-Ulugbeksky raion, 100007, Tashkent, Uzbekistan

Gulchekhra T. Tashmetova, Assistant, Department of Pulmonology with Course of Clinical Allergology

Tel.: + (998 71) 268‑17‑44

Е-mail: gtashmetovad@mail.ru

VASCULAR STIFFNESS AND PULMONARY FIBROSIS AS PREDICTORS OF RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION IN PATIENTS WITH CHRONIC HYPERSENSITIVITY PNEUMONITIS

Article 9.Page 65.
ARTICLE TITLE:

VASCULAR STIFFNESS AND PULMONARY FIBROSIS AS PREDICTORS OF RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION IN PATIENTS WITH CHRONIC HYPERSENSITIVITY PNEUMONITIS

DOI: 10.7868/S2587667820030097

AUTORS:

Leonova E.I., Shmelev E.I., Shergina E.A.

Central ТВ Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 22.05.2020

The high level of cardiovascular comorbidities in patients with lung diseases requires a study of risk factors for cardiovascular complications. Vascular wall stiffness as an independent risk factor for cardiovascular events remains unexplored in patients with interstitial lung diseases. Aim: To study a prognostic role of increased arterial stiffness in the development of right ventricular dysfunction in patients with chronic hypersensitivity pneumonitis (HP). Materials and methods: One hundred and six patients with chronic HP were observed in our clinic for two years. Spirometry, plethysmography, diffusing capacity of carbon monoxide (DLCO), blood gases, echocardiography, and pulse wave velocity (PWV) were evaluated. The extent of lung fibrosis was assessed using high-resolution computed tomography of the chest. Results. In the Cox proportional hazards model two variables significantly predicted right ventricular systolic dysfunction: the extent of pulmonary fibrosis and PWV (p < 0.05). Conclusion. The increase of arterial stiffness and the extent of pulmonary fibrosis can be used as predictors of right ventricular systolic dysfunction in chronic HP patients.

The article was prepared under scientific theme 0515‑2019‑0014 “Improving methods of treatment of granulomatous, interstitial and non-specific lung diseases”.

REFERENCES:
  1. Karoli N.I., Dolishnyaya G.R., Rebrov A.P. Daily indicators of arterial rigidity of men with various phenotypes of chronic obstructive pulmonary disease in combination with arterial hypertension. Klinitsist, 2015, vol. 1, no. 1, pp. 37–41. (In Russ.)
  2. Makarova M.A., Avdeev S.N., Chuchalin A.G. Hypoxemia as a potential risk factor of endothelial dysfunction and arterial stiffness in patients with chronic obstructive pulmonary disease. Pulmonologiya, 2013, no. 3, pp. 36–40. (In Russ.)
  3. Akintunde A.A. Right ventricular function in patients with heart failure in a cardiac clinic in Southwest Nigeria. Nigerian Medical Journal: Journal of the Nigeria Medical Association, 2017, vol. 58, no. 1, pp. 7–12.
  4. Al-Naamani N., Chirinos J.A., Zamani P., Ruthazer R., Paulus J.K., Roberts K.E., Barr R.G., Lima J.A., Bluemke D.A., Kronmal R., Kawut S.M. Association of systemic arterial properties with right ventricular morphology: The Multi-Ethnic Study of Atherosclerosis (MESA)-Right Ventricle Study. J. Am. Heart. Assoc., 2016, vol. 5, no. 12, pp. 1–11.
  5. Ben-Shlomo Y., Spears М., Boustred Сh., May M., Anderson S.G., Benjaminet E.J. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J. Am. Coll. Cardiol., 2014, vol. 3, no. 7, pp. 636–646.
  6. Broder M., Change E., Papoyan E., Popescuet I. Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: analysis of Medicare data. Eur. Respir. J., 2016, vol. 48, no. 60, pp. 1113–1130.
  7. Dalleywater W., Powell H.A., Hubbard R.B., Navaratnam V. Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a populationbased study, Chest, 2015, vol. 147, no. 1, pp. 150–156.
  8. Galderisi M., Cosyns B., Edvardsen T., Cardim N., Delgado V., Di Salvo G. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging, Eur. Heart J. Cardiovasc. Imaging, 2017, vol. 18, no. 12, pp. 1301–1310.
  9. Hsia C.C. Cardiopulmonary limitations to exercise in restrictive lung disease. Med. Sci. Sports Exerc., 1999, vol. 31, no. 1, pp. 28–32.
  10. Kazerooni E.A., Martinez F.J., Flint A., Jamadar D.A., Gross B.H., Spizarny D.L. Thin-section CT obtained at 10-mm increments versus limited three-level thinsection CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am. J. Roentgenol., 1997, vol. 169, no. 4, pp. 977–983.
  11. Kolb T.M., Hassoun P.M. Right ventricular dysfunction in chronic lung disease. Cardiol. Clin., 2012, vol. 30, no. 2, pp. 243–256.
  12. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr., 2015, vol. 28, no. 1, pp. 1–39.
  13. Panagiotou M., Church A.C., Johnson M.K., Peacock A.J. Pulmonary vascular and cardiac impairment in interstitial lung disease. European Respiratory Review, 2017, vol. 26, no. 1, pp. 1–9.
  14. Rivera-Lebron B.N., Forfia P.R., Kreider M., Lee J.C., Holmes J.H., Kawut S.M. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest, 2013, vol. 144, no. 2, pp. 564–570.
  15. Rudski L.G., Lai W.W., Afilalo J., Hua L., Handschumacher M.D., Chandrasekaran K., Solomon S.D., Louie E.K., Schiller N.B. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr., 2010, vol. 23, no. 7, pp. 685–713.
  16. Swift A.J., Rajaram S., Capener D., Hill C., Davies C., Hurdman J. Right ventricular dysfunction in pulmonary hypertension with combined pulmonary fibrosis and emphysema syndrome. European Respiratory Journal, 2013, vol. 42, p. 4081.
  17. Townsend R.R., Wilkinson I.B., Schiffrin E.L., Avolio A.P., Chirinos J.A., Cockcroft J.R., Heffernan K. Set. American Heart Association Council on Hypertension. recommendations for improving and standardizing vascular research on arterial stiffness. A Scientific Statement from the American Heart Association. J., 2015, vol. 66, no. 3, pp. 698–722.
  18. Van Bortel L.M., Laurent S., Boutouyrie P., Chowienczyk P., Cruickshank J.K., De Backer T. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J. Hypertens, 2012, vol. 30, no. 3, pp. 445–448.
  19. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and metaanalysis. Journal of the American College of Cardiology, 2010, vol. 55, no. 13, pp. 1318–1327.
  20. Vriz O., Magne J., Jarosh J., Bossone E. Local carotid arterial stiffness is an independent determinant of left ventricular remodeling in never-treated hypertensive patients. Blood pressure, 2018, vol. 22, no. 1, pp. 1–10.
KEYWORDS:

heart failure, vascular stiffness, chronic hypersensitive pneumonitis.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Elena I. Leonova, Candidate of Medical Sciences, Senior Researcher, Department of Differential Diagnosis of TB and Extracorporal Treatments

Tel.: +7 (906) 755‑36‑54

Е-mail: zei86@mail.ru

Evgeny I. Shmelev, Doctor of Medical Sciences, Professor, Head, Department of Differential Diagnosis

of TB and Extracorporal Treatments

Tel.: +7 (499) 785‑90‑08

Е-mail: eishmelev@mail.ru

Elena A. Shergina, Candidate of Medical Sciences. Head, Functional Diagnosis Department

Tel.: +7 (917) 526‑27‑75

Е-mail: e.a.sher@yandex.ru

THE CULTURE METHOD FOR MYCOBACTERIA STUDIES. SOLID GROWTH MEDIA

Article 10.Page 75.
ARTICLE TITLE:

THE CULTURE METHOD FOR MYCOBACTERIA STUDIES. SOLID GROWTH MEDIA

DOI: 10.7868/S2587667820030103

AUTORS:

Larionova E.E., Andrievskaya I.Yu., Andreevskaya S.N., Smirnova T.G., Sevastyanova E.V.

 

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 16.06.2020

 

The article represents a review of current solid media for mycobacteria growth. The principles of solid media preparation are outlined. The actual methods of solid egg media preparation are given. The article also describes the technique of inoculating solid growth media, the way of assessing results, and the methods of mycobacteria identification.

The article was prepared under research topic no. 0515-2019-0015: “The development of drug resistance of mycobacteria and somatic cells to TB drugs”.

REFERENCES:
  1. Guide to medical microbiology. Private medical microbiology and etiological diagnostics of infections. Book II. Ed. by A.S. Labinskaya, N.N. Kostukova, S.M. Ivanova. Moscow, Binom, 2010, 1151 p. (In Russ.)
  2. Finn E.R. Cultivation of Mycobacterium tuberculosis on different media and combinations of media. Lechebnoye delo, 1970, no. 10, p. 20. (In Russ.)
  3. Finn E.R. Ways of increasing inoculation and growth acceleration of Mycobacterium tuberculosis. Problems of Tuberculosis, 1974, no. 12, p. 72. (In Russ.)
  4. Chernousova L.N., Puzanov V.A., Andreevskaya S.N., Smirnova T.G., Larionova E.E., Popov S.A. Laboratory diagnosis of TB. Educational materials for the thematic refreshment cycle. Ed. by V.V. Erokhin. Moscow, 2012, 707 p. (In Russ.)
  5. Chernousova L.N., Sevastyanova E.V., Larionova E.E., Smirnova T.G., Andreevskaya S.N., Popov S.A., Zhuravlev V.Yu., Puzanov V.A., Maryandyshev A.O., Vakhrusheva D.V., Kravchenko M.A., Safonova S.G., Vasilyeva I.A., Ergeshov A.E. Federal clinical recommendations in organization and implementation of microbiological and molecular-genetic diagnostics of tuberculosis. ROF, Moscow, 2015, 35 p. (In Russ.)
  6. Cohn M.L., Waggoner R.F., McClatchy J.K. The 7H11 medium for the cultivation of mycobacteria. Am. Rev. Respir. Dis., 1968, vol. 98, no. 2, pp. 295–296.
  7. Cook G.M., Berney M., Gebhard S., Heinemann M., Cox R.A., Danilchanka O., Niederweis M. Physiology of mycobacteria. Adv. Microb. Physiol., 2009, vol. 55, pp. 318–319.
  8. Cummings M.M. Diagnostic methods in tuberculosis. II. Demonstration of Mycobacterium tuberculosis by culture. Am. J. Clin. Pathol., 1951, vol. 21, pp. 684–698.
  9. Dubos R.J., Fenner F., Pierce C.H. Properties of a culture of BCG grown in liquid media containing Tween 80 and filtrate of heated serum. Am. Rev. Tuberc.Pulm. Dis., 1950, vol. 61, no. 1, pp. 66–76.
  10. Dubos R.J., Middlebrook G. Media for Tubercle Bacilli, Am. Rev. Tuberculosis, 1947, vol. 56, no. 4, pp. 334–345.
  11. European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic methods for the European Union. Stockholm, ECDC, 2016, 111 p.
  12. Gruft H. Isolation of Acid-fast bacilli from contaminated specimens. Health Lab. Sci., 1971, vol. 8, no. 2, pp. 79–82.
  13. Jensen K.A. Human and bovine forms of tubercle bacilli. Schweiz Z. Pathol. Bakteriol. 1949, vol. 12, no. 5, pp. 435–450.
  14. Jensen K.A. Pure breeding and type determination of tubercle bacilli strains. A simplification of the methods for practice. Parasitenkd. Infektionskr., 1932, vol. I, pp. 125–222.
  15. Koch R. On the etiology of tuberculosis. From negotiations of the Congress of Internal Medicine. I. Congresses Wiesbaden 1882. Publisher F. Bergmann. Quoted from Collected Works by R. Koch, Leipzig, 1912, vol. 1, p. 446.
  16. Kubica G.P., Dye W.E., Cohn M.L., Middlebrook G. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. Am. Rev. Respir. Dis., 1963, vol. 87, p. 775.
  17. Kubica G.P., Kaufmann A.J., Dye W.E. Comments on the use of the new mucolytic agent, N-acetyl-L-cysteine, as a sputum digestant for the isolation of mycobacteria. Am. Rev. Respir. Dis., 1964, vol. 89, p. 284.
  18. Liu P.I., McGregor D.H., Faucher I., Jinks W.L., Miller L.A., Green L., Liu J.G. Comparison of three culture media for isolation of Mycobacterium tuberculosis: a 6-year study. Appl. Microbiol., 1973, vol. 26, 880–883.
  19. Lowenstein E. The cultivation of the tubercle bacilli from the flowing blood. Zentralb. Bacteriol. Parasitenkd. Infektionskr., 1931, vol. I, pp. 120–127.
  20. MacFaddin J.F. Media for isolation – cultivation –identification – maintenance of medical bacteria. 1985, Baltimore, London, 929 p.
  21. Middlebrook G., Cohn M.L. Bacteriology of tuberculosis laboratory methods. Am. J. Public Health Nations Health, 1958, 48, no. 7, pp. 844–853.
  22. Petragnani G. Modifications in technique of isolating Koch’s bacillus. Boll. Ist. Sieroter. Milan., 1926, vol. 5, no. 3, pp. 173–182.
  23. Atlas R.M., Snyder J.W. Handbook of media for clinical and public health microbiology. 2014, 561 p.
  24. Schaefer W.B., Cohn M.L., Middlebrook G. The roles of biotin and carbon dioxide in the cultivation of Mycobacterium tuberculosis. J. Bacteriol., 1955, vol. 69, no. 6, pp. 706–712.
  25. Somlo A.M., Black T.C., Somlo L.I. The value of fluorescent microscopy in the detection of acid-port bacilli. Tech. Bull. Regist. Med. Technol., 1969, vol. 39, no. 3, pp. 51–54.
  26. Global tuberculosis report. Geneva, WHO, 2019, 297 p.
KEYWORDS:

mycobacteria, culture method, solid growth medium.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Elena E. Larionova, Candidate of Biological Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: larionova_lena@mail.ru

Irina Yu. Andrievskaya, Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: andrievskaya.iri@mail.ru

Sofia N. Andreevskaya, Candidate of Medical Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: andsofia@mail.ru

Tatiana G. Smirnova, Candidate of Medical Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: s_tatka@mail.ru 

Elina V. Sevastyanova, Doctor of Biological Sciences, Leading Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: elinasev@yandex.ru